Alain Beck, Ph.D.

Senior Biologics CMC & Developability Director at Pierre Fabre Group

The current 13 ADCs approved world-wide, targeting hematological malignancies (CD33, CD30, CD22, CD79b, BCMA, CD19) and solid tumors (high or low HER2, Nectin-4, TROP-2, tissue factor, FR alpha) are success benchmarks. In addition, more than 10 are in regulatory review or late-stage clinical trials including site-specific and high-loaded payloads. But near 100 have also failed in clinical trials. Lessons learned will be discussed as well as alternative formats, payloads, linkers, conjugation technologies currently investigated in preclinical or early clinical phases.

Dr Alain Beck is Senior Director, Biologics CMC and Developability (Pierre Fabre), co-founder and Associate Editor of mAbs (2009, https://www.tandfonline.com/journals/kmab20) and chairman of MabDesign SAB (2014, www.mabdesign.fr). He is or was involved in +10 clinical stage biologics R&D programs including dalotuzumab (Merck), telisotuzumab/ telisotuzumab vedotin (AbbVie), lonigutamab ugodotin ADC and W0180 Vista mAb (PF), ER004 Fc-fusion protein (www.esperare.org) and VB421/ lonigutamab (www.valenzabiotech.com). He is author/ co-author of +255 publications (h-index: 63; +14,600 citations). He has contributed to +300 scientific meetings (AET, AIS, BAS, Bioproduction, CASSS, CTDP, EAC, FOB, GlycoBiotec, PEGS, SCT, WADC, WBC, WCBP) as chairman, invited speaker, panellist, moderator, advisor, and/or organizer (IO mAbs, ADCs, Biobetters, Biosimilars, pAbs, Bs/MsAbs, Fc-fusions, Immunocytokines, Protein Scaffolds, Mass Spec, Med Chem, PK/PD, separative sciences). He was ranked 6/50 global antibody industry influencers (2013) and was the 6th WADC (2019) and the 10th AIS Award winner (2022) for long and outstanding contribution in the field. He is member of the MAB Working Party (EDQM/PhEur) and involved in workshops with ANSM, EU, EMA, FDA, NIST, USP and WHO.